Pharmaceutical

Generics expected to improve access for patients with idiopathic pulmonary fibrosis

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments approved by the FDA in 2014.

Sep 27, 2023 - 20:00
Generics expected to improve access for patients with idiopathic pulmonary fibrosis
The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments approved by the FDA in 2014.
Read the original article

Tags:

Previous Article

Novo Nordisk and Evotec launch translational drug discovery accelerator

Next Article

Mobile health strategies: Should you build or partner for success?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio 

Novartis acquires Mariana in $1.75bn deal to strengthen...

May 3, 2024

STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys

STAT+: Why Novartis is going to walk away from its acqu...

Feb 7, 2024

STAT+: Senators delay start date for possible PBM reforms

STAT+: Senators delay start date for possible PBM reforms

May 1, 2023